Q-omics provides the consensus-scored RABGAP1L-IT1 profile across patient tissues and cancer cell-line models. RABGAP1L-IT1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RABGAP1L-IT1 is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, RABGAP1L-IT1 RNA expression shows 10,725 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, STAD, and GBM as cancer lineages where RABGAP1L-IT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RABGAP1L-IT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RABGAP1L-IT1 survival associations across molecular data types. RABGAP1L-IT1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RABGAP1L-IT1 RNA expression–survival associations across cancer types. High RABGAP1L-IT1 expression shows unfavorable associations in KIRC, HNSC, THCA and ACC, but favorable associations in BRCA and BLCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for RABGAP1L-IT1 RNA expression.
This table summarizes RABGAP1L-IT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RABGAP1L-IT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RABGAP1L-IT1 shows lower tumor expression in KIRP and higher tumor expression in STAD, LIHC, BRCA, ESCA and HNSC. The STAD box plot shows higher RABGAP1L-IT1 RNA expression in tumor versus normal tissue (log2 FC = +0.663, t-test p < 0.001).
This table shows molecular features associated with RABGAP1L-IT1 in patient tissues and cancer cell lines. In patient samples, RABGAP1L-IT1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
